↓ Skip to main content

Governance and pharmacovigilance in Brazil: a scoping review

Overview of attention for article published in Journal of Pharmaceutical Policy and Practice, February 2016
Altmetric Badge

About this Attention Score

  • Among the highest-scoring outputs from this source (#48 of 104)
  • Above-average Attention Score compared to outputs of the same age (64th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
4 tweeters

Citations

dimensions_citation
20 Dimensions

Readers on

mendeley
87 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Governance and pharmacovigilance in Brazil: a scoping review
Published in
Journal of Pharmaceutical Policy and Practice, February 2016
DOI 10.1186/s40545-016-0053-y
Pubmed ID
Authors

Kathy Moscou, Jillian C. Kohler, Anita MaGahan

Abstract

This scoping review investigates the relationship between governance, pharmacovigilance, and Agencia Nacional de Vigilancia Sanitaria (ANVISA) in Brazil, which has authority over Brazil's national pharmaceutical policy, drug registration and coordination of the national pharmacovigilance system. The purpose is to investigate opportunities for effective pharmacovigilance. Sixty-three terms pertaining to pharmacovigilance in Brazil and ANVISA, global institutions, pharmaceutical industry, and civil society were searched in thirteen relevant databases on November 17-18, 2013. Using a pharmacogovernance framework we analyzed ANVISA's pharmacogovernance: the manner in which governing structures, policy instruments, and institutional authority are managed to promote societal interests for patient safety due to medication use. The integration of transnational policy ideas for regulatory governance into pharmacogovernance in Brazil was also investigated. Brazil's policy, laws, and regulations support ANVISA's authority to ensure access to safe medicines and health products however ANVISA's broad mandate and gaps in pharmacogovernance account for regional disparities in monitoring and assessing drug safety. Gaps in pharmacogovernance include: equity and inclusiveness; stakeholder coordination; effectiveness and efficiency; responsiveness; and intelligence and information. Pharmacogovernance that addresses 1) regional resource disparities, 2) federal and state lack of coordination of pharmacovigilance regulations, 3) asymmetric representation in the pharmaceutical regulatory agenda and which 4) disaggregates regulatory authority over health and commercial sectors would strengthen pharmacovigilance in Brazil.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 87 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Brazil 1 1%
Unknown 84 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 17 20%
Student > Bachelor 11 13%
Researcher 9 10%
Student > Doctoral Student 9 10%
Student > Ph. D. Student 6 7%
Other 19 22%
Unknown 16 18%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 22 25%
Medicine and Dentistry 14 16%
Nursing and Health Professions 9 10%
Biochemistry, Genetics and Molecular Biology 5 6%
Business, Management and Accounting 3 3%
Other 16 18%
Unknown 18 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 April 2016.
All research outputs
#2,936,865
of 7,520,778 outputs
Outputs from Journal of Pharmaceutical Policy and Practice
#48
of 104 outputs
Outputs of similar age
#112,009
of 325,632 outputs
Outputs of similar age from Journal of Pharmaceutical Policy and Practice
#5
of 8 outputs
Altmetric has tracked 7,520,778 research outputs across all sources so far. This one has received more attention than most of these and is in the 60th percentile.
So far Altmetric has tracked 104 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 325,632 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 64% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.